CA2063810A1 - Production of vascular endothelial cell growth factor - Google Patents

Production of vascular endothelial cell growth factor

Info

Publication number
CA2063810A1
CA2063810A1 CA002063810A CA2063810A CA2063810A1 CA 2063810 A1 CA2063810 A1 CA 2063810A1 CA 002063810 A CA002063810 A CA 002063810A CA 2063810 A CA2063810 A CA 2063810A CA 2063810 A1 CA2063810 A1 CA 2063810A1
Authority
CA
Canada
Prior art keywords
growth factor
cell growth
vascular endothelial
endothelial cell
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002063810A
Other languages
French (fr)
Other versions
CA2063810C (en
Inventor
Edmund G. Tischer
Judith A. Abraham
John C. Fiddes
Richard L. Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Edmund G. Tischer
Judith A. Abraham
John C. Fiddes
Richard L. Mitchell
California Biotechnology Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edmund G. Tischer, Judith A. Abraham, John C. Fiddes, Richard L. Mitchell, California Biotechnology Inc. filed Critical Edmund G. Tischer
Publication of CA2063810A1 publication Critical patent/CA2063810A1/en
Application granted granted Critical
Publication of CA2063810C publication Critical patent/CA2063810C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/49Platelet-derived growth factor [PDGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

Isolated DNA sequences, expression vectors and transformant cells are provided which allow for the large scale produc-tion of vascular endothelial cell growth factor. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.
CA002063810A 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor Expired - Lifetime CA2063810C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38754589A 1989-07-27 1989-07-27
US387,545 1989-07-27
US450,883 1989-12-14
US07/450,883 US5194596A (en) 1989-07-27 1989-12-14 Production of vascular endothelial cell growth factor
PCT/US1990/004227 WO1991002058A1 (en) 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor

Publications (2)

Publication Number Publication Date
CA2063810A1 true CA2063810A1 (en) 1991-01-28
CA2063810C CA2063810C (en) 2003-02-04

Family

ID=27011922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002063810A Expired - Lifetime CA2063810C (en) 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor

Country Status (10)

Country Link
US (1) US5194596A (en)
EP (1) EP0484401B1 (en)
JP (4) JP3523645B2 (en)
AT (1) ATE142693T1 (en)
AU (1) AU6079890A (en)
CA (1) CA2063810C (en)
DE (1) DE69028535T2 (en)
DK (1) DK0484401T3 (en)
ES (1) ES2094159T3 (en)
WO (1) WO1991002058A1 (en)

Families Citing this family (434)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
DE69030660T2 (en) * 1989-03-24 1997-09-25 Univ California ENDOTHELIAL CELL GROWTH FACTOR, INSULATION AND EXPRESSION
US6899882B1 (en) 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
DE69024261T2 (en) * 1989-05-24 1996-07-18 Merck & Co Inc Purification and characterization of a growth factor derived from a glioma
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2064331C (en) * 1991-03-28 2003-02-18 Marvin L. Bayne Vascular endothelial cell growth factor c subunit
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5514779A (en) * 1991-06-07 1996-05-07 Zeneca Limited Biocidal proteins from plants
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
ATE238417T1 (en) * 1991-11-04 2003-05-15 Inst Genetics Llc RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (en) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
AU5125693A (en) * 1992-09-03 1994-03-29 Regents Of The University Of California, The Dorsal tissue affecting factor and compositions
ATE215565T1 (en) * 1992-10-28 2002-04-15 Genentech Inc USE OF ANTI-VEGF ANTIBODIES TO TREAT CANCER
AU6778794A (en) * 1993-04-29 1994-11-21 Washington University Use of platelet-derived growth factor to improve collateral circulation
DE69434053T2 (en) * 1993-06-29 2006-02-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville REDUCED KERATINOCYTE GROWTH FACTOR (KGF) WITH INCREASED BIOLOGICAL ACTIVITY
WO1995006131A1 (en) * 1993-08-23 1995-03-02 Monash University A method for the assay, prophylaxis and/or treatment of human disease conditions
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CA2179638A1 (en) * 1993-12-24 1995-07-06 Peter Schulz-Knappe Human circulating cytokine cc-1
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
CA2184584C (en) * 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
WO1996000286A1 (en) * 1994-06-27 1996-01-04 Toagosei Co., Ltd. Antisense nucleic acid compound
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
AU720270B2 (en) * 1995-02-09 2000-05-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleotide and deduced amino acid sequences of tumor gene Int6
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) * 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
ES2206558T3 (en) * 1995-03-02 2004-05-16 Amrad Operations Pty.,Ltd. NEW GROWTH FACTOR AND GENETIC SEQUENCE THAT CODIFIES IT.
US7160991B1 (en) * 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
JPH11503012A (en) * 1995-03-30 1999-03-23 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド Human G protein-coupled receptor
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US7429646B1 (en) * 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) * 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US20020150578A1 (en) * 1995-06-05 2002-10-17 Human Genome Sciences, Inc. Human prostatic specific reductase
US20020026037A1 (en) * 1995-06-06 2002-02-28 Jing-Shan Hu Vascular endothelial growth factor 3 antibodies
US6013483A (en) * 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
DE69624925T2 (en) * 1995-08-15 2003-09-04 Connetics Corp USE OF RELAXIN TO STIMULATE ANGIOGENESIS
EP1382679A3 (en) 1995-09-08 2004-11-10 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
CA2230957A1 (en) * 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
US6329169B1 (en) * 1995-09-29 2001-12-11 Human Genome Sciences, Inc. Nucleic acid molecules encoding cytostatin II
AU717277B2 (en) * 1995-10-23 2000-03-23 Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US7393943B1 (en) * 1995-12-08 2008-07-01 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic cytokine I
US7888466B2 (en) * 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7084252B1 (en) * 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
AU725295B2 (en) * 1996-01-22 2000-10-12 Brandeis University Morphogen analogs and methods for producing them
JP3930052B2 (en) 1996-02-15 2007-06-13 バイオセンス・インコーポレイテッド Catheter-based surgery
US6713061B1 (en) * 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6410268B1 (en) 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
DE69739469D1 (en) * 1996-08-23 2009-07-30 Vegenics Ltd Recombinant vascular endothelial growth factor D (VEGF-D)
US20030129643A1 (en) * 1996-08-23 2003-07-10 Human Genome Sciences, Inc. T1 receptor-like ligand I
AU731647B2 (en) * 1996-08-27 2001-04-05 Atsunobu Hiraoka Hematopoietic stem cell growth factor (SCGF)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
EP0928203B1 (en) 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US6998418B1 (en) 1996-11-05 2006-02-14 Gp Medical, Inc. Acellular biological material chemically treated with genipin
US20060171907A1 (en) * 1996-11-21 2006-08-03 The Procter & Gamble Company Oral care compositions providing enhanced whitening and stain prevention
DE69738841D1 (en) * 1996-12-23 2008-08-28 Immunex Corp LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CN1247567A (en) * 1997-01-14 2000-03-15 人体基因组科学有限公司 Tumor necrosis factor receptor alfa 6 and receptor beta 6
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
AU6030398A (en) * 1997-01-21 1998-08-07 Auckland Uniservices Limited Human proteins
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US20020155538A1 (en) * 1997-01-23 2002-10-24 Incyte Pharmaceuticals, Inc. Novel endothelial growth factor
WO1998033918A1 (en) * 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
WO1998035039A1 (en) * 1997-02-06 1998-08-13 Human Genome Sciences, Inc. Dendritic cell-derived growth factor
US6395707B1 (en) 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US7968689B2 (en) * 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
WO1998039035A1 (en) 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
WO2000035937A1 (en) * 1998-12-17 2000-06-22 Human Genome Sciences, Inc. 47 human secreted proteins
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1005355A4 (en) * 1997-04-15 2002-07-17 Radix Organization Inc Method of treating gastrointestinal ulcers and compositions therefor
US7205381B2 (en) * 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
US20030166065A1 (en) * 1997-04-24 2003-09-04 Human Genome Sciences, Inc. Novel integrin ligand ITGL-TSP
US7220557B2 (en) * 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
EP0979282A1 (en) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6031155A (en) * 1997-06-05 2000-02-29 Cameron-Mills; Verena Arabinoxylan degradation
US20060223077A1 (en) * 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US5891674A (en) * 1997-06-19 1999-04-06 Incyte Pharmaceuticals, Inc. Insulin receptor tyrosine kinase substrate
CA2295303A1 (en) * 1997-06-27 1999-01-07 Human Genome Sciences Inc. Human nk-3 related prostate specific gene-1
US6635480B1 (en) * 1997-07-31 2003-10-21 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
AU8586198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor, lefty-1
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
WO1999025825A2 (en) * 1997-11-13 1999-05-27 Genset EXTENDED cDNAs FOR SECRETED PROTEINS
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
US20020112251A1 (en) * 1997-08-04 2002-08-15 Mccarthy Sean A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
FR2767135B1 (en) * 1997-08-06 2002-07-12 Genset Sa LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US6849719B2 (en) * 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU9482498A (en) * 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US20030077654A1 (en) * 1997-09-17 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1018551A4 (en) * 1997-09-22 2003-07-23 Toshio Miyata Megsin protein
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) * 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US20060286639A1 (en) * 1997-11-13 2006-12-21 Serono Genetics Institute S.A. Complementary DNAs encoding proteins with signal peptides
US20060009633A9 (en) * 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
AU763012B2 (en) 1997-11-22 2003-07-10 Arca Biopharma, Inc. A novel EGF motif protein obtained from a cDNA library of fetal liver-spleen
US20030096742A1 (en) * 1997-12-03 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999029854A1 (en) * 1997-12-08 1999-06-17 Ontogeny, Inc. Human patched genes and proteins, and uses related thereto
US6303770B1 (en) * 1997-12-10 2001-10-16 Zymogenetics, Inc. Nucleic acids encoding mammalian alpha helical protein-1
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6703485B2 (en) * 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
ATE395928T1 (en) * 1997-12-24 2008-06-15 Ludwig Inst Cancer Res EXPRESSION VECTORS AND CELL LINES FOR EXPRESSING VASCULAR GROWTH FACTOR D, AND METHOD FOR TREATING MELANOMAS
JPH11187884A (en) * 1997-12-26 1999-07-13 Hsp Kenkyusho:Kk Beat shock transcription factor-binding protein
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2451199A (en) * 1998-01-07 1999-07-26 Human Genome Sciences, Inc. 36 human secreted proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7722671B1 (en) 1998-01-27 2010-05-25 St. Jude Medical, Inc. Medical devices with associated growth factors
ES2293473T3 (en) 1998-02-05 2008-03-16 Biosense Webster, Inc. INTRACARDIAC ADMINISTRATION OF FARMACO.
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
NZ505955A (en) 1998-02-06 2005-04-29 Collateral Therapeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF-A, and pharmaceutical use
US6706869B1 (en) * 1998-02-11 2004-03-16 Wyeth Map kinase phosphatases and polynucleotides encoding them
US6395890B1 (en) * 1998-02-20 2002-05-28 Zymogenetics, Inc. Nucleic acids encoding connective tissue growth factor homologs
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20050026248A1 (en) * 1998-03-26 2005-02-03 Hsueh Aaron J.W. Novel mammalian G-protein coupled receptors having extracellular leucine rich repeat regions
DE19813774A1 (en) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF)
US6573095B1 (en) * 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
KR20010043583A (en) * 1998-05-14 2001-05-25 우에노 도시오 NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF
US7125959B2 (en) * 1998-05-15 2006-10-24 Genentech, Inc. PRO4405 polypeptides
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
AU4411499A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
US20070020724A1 (en) 1998-06-16 2007-01-25 Ruben Steven M 94 human secreted proteins
SK287361B6 (en) * 1998-07-14 2010-08-09 Janssen Pharmaceutica N. V. Human neurotrophic growth factor and use thereof
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
US20050048612A1 (en) * 1998-07-28 2005-03-03 Incyte Corporation Human epidermal proteins HEP1-1 to HEP1-6
US6706951B1 (en) * 1998-08-17 2004-03-16 Pioneer Hi-Bred International, Inc. Maize nucleic acid encoding a GDP-mannose pyrophosphorylase
WO2000011199A1 (en) * 1998-08-20 2000-03-02 Pioneer Hi-Bred International, Inc. COMPOSITIONS AND METHODS FOR ALTERING AN ACETYL-CoA METABOLIC PATHWAY OF A PLANT
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
WO2000012707A1 (en) * 1998-09-02 2000-03-09 Millennium Pharmaceuticals, Inc. 14926 receptor, a novel g-protein coupled receptor
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (en) * 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
EP1112083B1 (en) * 1998-09-09 2003-11-12 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
JP2002525054A (en) * 1998-09-17 2002-08-13 インサイト・ファーマスーティカルズ・インコーポレイテッド Human GPCR protein
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
JP2002525117A (en) * 1998-09-30 2002-08-13 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド SLGP protein and nucleic acid molecules and uses thereof
JP2002527401A (en) * 1998-10-13 2002-08-27 カイロン コーポレイション Angiogenically effective unit dose of FGF and method of administration
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
AU1716200A (en) * 1998-11-12 2000-06-05 Human Genome Sciences, Inc. 31 human secreted proteins
US6375680B1 (en) 1998-12-01 2002-04-23 St. Jude Medical, Inc. Substrates for forming synthetic tissues
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2000189171A (en) * 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd New guanosine triphosphate(gtp)-binding protein conjugated receptor protein
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2856400A (en) * 1999-01-25 2000-08-07 University Of Florida Materials and methods for producing geminivirus resistant plants
AU3590000A (en) * 1999-02-02 2000-08-25 Trustees Of Columbia University In The City Of New York, The Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
JP2002540763A (en) * 1999-02-10 2002-12-03 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 33 human secreted proteins
DE19906096A1 (en) * 1999-02-13 2000-08-17 Walter Sebald Protein with a heparin-binding epitope
US6392126B1 (en) * 1999-02-25 2002-05-21 Pioneer Hi-Bred International, Inc. Adenosine deaminase homologues and uses thereof
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6406907B1 (en) * 1999-02-26 2002-06-18 Iowa State University Research Foundation Bovine tumor necrosis factor receptor-1 and methods of use
AU2878600A (en) * 1999-03-01 2000-09-21 Hadasit Medical Research Services & Development Company Ltd Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
IL128852A0 (en) * 1999-03-05 2000-01-31 Compugen Ltd Novel nucleic acid and amino acid sequences
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US6689866B1 (en) * 1999-03-09 2004-02-10 Curagen Corporation Polynucleotides and proteins encoded thereby
US8410248B2 (en) * 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
US6965012B1 (en) * 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
WO2000061757A1 (en) * 1999-04-12 2000-10-19 Genentech, Inc. Tumor necrosis factor homologs and nucleic acids encoding the same
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
CA2371702A1 (en) * 1999-04-30 2000-11-09 Toshio Miyata Meg-3 protein
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CA2373822A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants
JP2003500053A (en) * 1999-05-20 2003-01-07 サイオス,インコーポレーテッド Vascular endothelial growth factor dimer
WO2000071577A1 (en) * 1999-05-25 2000-11-30 Human Genome Sciences, Inc. Meth1 and meth2 polynucleotides and polypeptides
US20030207793A1 (en) * 1999-05-26 2003-11-06 Conklin Darrell C. Secreted alpha-helical protein - 32
JP2003501072A (en) * 1999-06-07 2003-01-14 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 26 human secreted proteins
US6781028B1 (en) * 1999-06-14 2004-08-24 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
US20030153050A1 (en) * 1999-06-28 2003-08-14 Conklin Darrell C. Helical polypeptide zalpha29
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
US6951738B2 (en) * 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
CA2696819C (en) * 1999-07-23 2015-07-07 Kenji Kangawa Ghrelin related peptides
WO2001010891A2 (en) * 1999-08-05 2001-02-15 Research Corporation Technologies, Inc. Il-16 antagonists
US20030134788A1 (en) * 1999-08-12 2003-07-17 Baker Kevin P. Human tumor necrosis factor receptor TR16
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
KR100510795B1 (en) * 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US20030120037A1 (en) * 1999-09-22 2003-06-26 Ji Ming Wang Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
DE60039708D1 (en) * 1999-10-18 2008-09-11 Lexicon Pharmaceuticals Inc HUMAN CHORDIN AND POLYNUCLEOTIDES THAT CODE FOR THIS
US7459308B2 (en) * 1999-10-21 2008-12-02 Arbor Vita Corporation Nucleic acid molecule encoding a CLASP-2 transmembrane protein
US6726718B1 (en) 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
US7029857B1 (en) * 1999-12-17 2006-04-18 H. Lundbeck A/S Processes for obtaining compounds employing SNORF72 receptors
JP2001211886A (en) * 2000-02-07 2001-08-07 Japan Science & Technology Corp Non-sodium-dependent small neutral amino acid transporter transporting l- and d-amino acids and its gene
CA2399387C (en) * 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
ATE377081T1 (en) 2000-02-25 2007-11-15 Ludwig Inst Cancer Res MATERIALS AND METHODS CONTAINING HYBRID VASCULAR DOTHELIAL GROWTH FACTORS DNA AND PROTEINS AND SCREENING METHODS FOR MODULATORS
US20030165891A1 (en) * 2000-02-29 2003-09-04 Millennium Pharmaceuticals, Inc. Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9 alpha2delta-4, 54414, and 53763 molecules and uses therefor
US6794187B2 (en) * 2000-03-03 2004-09-21 University Of Utah Research Foundation Mass1 gene, a target for anticonvulsant drug development
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20030119739A1 (en) * 2000-03-29 2003-06-26 Beth Israel Deaconess Medical Center Anti-angiogenic and anti-tumor properties of Vascostatin and other nidogen domains
US7070946B2 (en) * 2000-05-23 2006-07-04 Tanabe Seiyaku Co., Ltd. Bone metabolism related protein and gene thereof
AU2001241713C1 (en) * 2000-05-31 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. DNAs encoding mammalian histamine receptor of the H4 subtype
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
AU8183601A (en) * 2000-06-21 2002-01-02 Merck Patent Gmbh A g-protein coupled receptor
EP1313512A4 (en) * 2000-08-04 2004-08-25 Human Genome Sciences Inc Vascular endothelial growth factor 2
US20020081700A1 (en) * 2000-08-07 2002-06-27 Sheppard Paul O. Snake venom polypeptide zsnk1
JP2004508043A (en) * 2000-09-05 2004-03-18 アムジェン インコーポレイテッド TNF receptor-like molecules and uses thereof
AU2002213259A1 (en) * 2000-10-13 2002-04-22 Hyseq, Inc. Egf motif protein, egfl6 materials and methods
US6489456B1 (en) * 2000-10-27 2002-12-03 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
GB0028971D0 (en) * 2000-11-28 2001-01-10 Inpharmatica Ltd Novel proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) * 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20030180309A1 (en) * 2001-01-08 2003-09-25 Baum Peter R. Human B7 polypeptides
US20030186904A1 (en) * 2001-01-08 2003-10-02 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002068587A2 (en) * 2001-02-07 2002-09-06 Bristol-Myers Squibb Company Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
CA2438934A1 (en) * 2001-02-23 2002-09-06 Wyeth Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7741049B2 (en) * 2001-03-15 2010-06-22 Sumitomo Chemical Company, Limited Analysis of agonist-activity and antagonist-activity to cytokinin receptor
US6962971B2 (en) * 2001-03-16 2005-11-08 The Regents Of The University Of California Chemokines and methods for inducing the differentiation of fibroblasts to myofibroblasts
EP1372698A2 (en) * 2001-03-23 2004-01-02 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders
AU2002303340A1 (en) * 2001-04-10 2002-10-28 Agensys, Inc. Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP1385862A4 (en) * 2001-04-13 2005-03-02 Human Genome Sciences Inc Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
US20030086872A1 (en) * 2001-08-15 2003-05-08 Jean-Philippe Girard SUT-2 and SUT-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
MXPA04001526A (en) * 2001-08-21 2004-05-31 Chiron Corp Kgf polypeptide compositions.
AU2002331669A1 (en) * 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
MXPA04001986A (en) * 2001-08-29 2004-06-07 Genentech Inc Compositions and methods for the treatment of immune related diseases.
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
US7097990B2 (en) * 2001-10-12 2006-08-29 Astellas Pharma Inc. Method of screening cell death inhibitor
EP1578907A2 (en) * 2001-10-17 2005-09-28 ZymoGenetics, Inc. Secreted protein, ztnf9
US7371258B2 (en) * 2001-10-26 2008-05-13 St. Jude Medical, Inc. Valved prosthesis with porous substrate
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
EP1474176A4 (en) * 2001-11-26 2005-06-15 Bristol Myers Squibb Co Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
US20030104496A1 (en) * 2001-11-30 2003-06-05 Cytokinetics, Inc. Novel motor protein of P. falciparum and methods for its use
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
CA2472927A1 (en) * 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
US20040162237A1 (en) * 2002-01-15 2004-08-19 Fox Niles Wayne Use of lp82 to treat body weight disorders
KR20030062789A (en) 2002-01-19 2003-07-28 포휴먼텍(주) Biomolecule transduction peptide sim2-btm and biotechnological products including it
KR20030062788A (en) 2002-01-19 2003-07-28 포휴먼텍(주) Biomolecule transduction peptide mph1-btm and biotechnological products including it
WO2003066808A2 (en) * 2002-01-23 2003-08-14 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
EP1474515A2 (en) * 2002-02-01 2004-11-10 Bayer HealthCare AG Regulation of human hematopoietin receptor-like protein
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
WO2003077652A1 (en) * 2002-03-12 2003-09-25 Harold Brem Method for treating diabetic ulcers
US20060263770A1 (en) * 2002-03-22 2006-11-23 Marco Colonna Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JP2005537783A (en) * 2002-03-28 2005-12-15 ザ ジェネティクス カンパニー インコーポレイティド Growth regulatory protein
CA2482718C (en) * 2002-04-18 2014-08-19 Yeda Research And Development Co. Ltd. Derivatives of the il-2 receptor gamma chain, their production and use
WO2003091282A1 (en) * 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Histamine receptor h3 ordinary activity mutant and utilization thereof
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1382613A1 (en) * 2002-07-16 2004-01-21 Sumitomo Chemical Company, Limited Novel G protein, polynucleotide encoding the same and utilization thereof
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
ES2440651T3 (en) * 2002-07-19 2014-01-29 Beth Israel Deaconess Medical Center Method to diagnose preeclampsia
GB0219303D0 (en) * 2002-08-19 2002-09-25 Ares Trading Sa Protein
AU2003267563A1 (en) * 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
BR0315155A (en) * 2002-10-08 2005-08-16 Ares Trading Sa Use of cytokine capable of binding to il-18bp and inhibiting the activity of a second cytokine
GB0223984D0 (en) * 2002-10-15 2002-11-20 Novartis Forschungsstiftung Methods for detecting teneurin signalling and related screening methods
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP4571776B2 (en) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 Lubricating oil composition
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
WO2004062621A2 (en) * 2003-01-13 2004-07-29 Georgia Tech Research Corporation Anti-inflammatory agents and methods of their use
WO2004069136A2 (en) * 2003-02-05 2004-08-19 Applied Research Systems Ars Holding N.V. Mucin-like polypeptides
DE602004027798D1 (en) * 2003-03-12 2010-08-05 Univ Arizona State METHOD FOR REGULATING ANGIOGENESIS WITH APELIN COMPOSITIONS
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
DE602004021648D1 (en) 2003-04-18 2009-07-30 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
WO2005110009A2 (en) * 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
KR100632985B1 (en) * 2003-07-26 2006-10-11 메덱스젠 주식회사 A method of improving efficacy of biological response-modifying proteins and the example muteins
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US7759472B2 (en) * 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP4723496B2 (en) * 2003-09-08 2011-07-13 メルク セローノ ソシエテ アノニム Treatment of fibrotic diseases
WO2005026344A1 (en) * 2003-09-11 2005-03-24 Hubit Genomix, Inc. Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases causing sclerosis
AU2004277954A1 (en) * 2003-09-29 2005-04-14 The Kenneth S Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20060104978A1 (en) * 2003-10-24 2006-05-18 Ludwig Institute For Cancer Research Methods and compositions for PDGF-C activation and inhibition
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005058957A2 (en) * 2003-12-16 2005-06-30 Zymogenetics, Inc. Ztnf 12, a tumor necrosis factor
DE602004013372T2 (en) 2003-12-30 2009-07-02 Merck Patent Gmbh IL-7 FUSION PROTEINS WITH ANTIBODY PORTIONS, THEIR PREPARATION AND THEIR USE
US20050176073A1 (en) * 2004-02-06 2005-08-11 Chemocentryx, Inc. Cell proliferation associated with CCX CKR expression
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
DE602005005392T2 (en) * 2004-06-30 2009-04-23 Tyco Electronics Nederland B.V. Connector for electronic components
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (en) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク. Synthetic advanced glycosylated protease resistant polypeptide variants, oral formulations and methods using the same
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
SE0402025D0 (en) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
DE602005022457D1 (en) * 2004-08-19 2010-09-02 Biogen Idec Inc Neublastin VARIATIONS
AR050608A1 (en) * 2004-08-19 2006-11-08 Alza Corp APPARATUS AND METHOD FOR TRANSDERMAL ADMINISTRATION OF VASCULAR ENDOTELIAL GROWTH FACTORS
ES2349043T3 (en) * 2004-08-19 2010-12-22 Biogen Idec Ma Inc. NEUBLASTIN VARIANTS.
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP1804836B1 (en) 2004-09-24 2010-11-17 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US20060090646A1 (en) * 2004-11-04 2006-05-04 Questair Technologies Inc. Adsorbent material for selective adsorption of carbon monoxide and unsaturated hydrocarbons
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
BRPI0519096A2 (en) * 2004-12-15 2008-12-23 Beth Israel Hospital Nucleic Acids and Polypeptides Useful for Diagnosing and Treating Pregnancy Complications
WO2006074397A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
ATE553122T1 (en) 2005-02-28 2012-04-15 Sangamo Biosciences Inc ANTIANGIOGENIC METHODS AND COMPOSITIONS
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
CN101137906A (en) * 2005-03-23 2008-03-05 惠氏公司 Detection of an immune response to gdf-8 modulating agents
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
MX2007015943A (en) * 2005-06-17 2008-03-07 Genentech Inc Wound healing.
JP2008547006A (en) * 2005-06-17 2008-12-25 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド Osteoarthritis protein profile
US8329175B2 (en) * 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
US7659250B2 (en) * 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
AU2006343279B2 (en) 2005-12-22 2012-03-29 Genentech, Inc. Recombinant production of heparin binding proteins
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
TWI501774B (en) * 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
GB0604460D0 (en) * 2006-03-06 2006-04-12 Isis Innovation Treatment
US9878003B2 (en) 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
WO2007130619A1 (en) * 2006-05-03 2007-11-15 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating osteoclast differentiation, activation and bone resorption
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
ES2532848T3 (en) * 2006-07-04 2015-04-01 Combigene Ab Use of nucleic acid sequences for the treatment of neurological and psychiatric diseases, vectors and compositions
EP2041154B1 (en) 2006-07-14 2018-12-12 Genentech, Inc. Refolding of recombinant proteins
US20100178271A1 (en) * 2006-08-07 2010-07-15 Genzyme Corporation Combination Therapy
US8865169B2 (en) * 2007-02-20 2014-10-21 Tufts University Methods and systems for multi-antibody therapies
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
KR100984483B1 (en) * 2007-03-19 2010-10-01 (주)바이오니아 Cyclic reverse transcription method
WO2008116111A2 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
WO2008116116A2 (en) * 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2476253T3 (en) * 2007-05-01 2014-07-14 Biogen Idec Ma Inc. Neublastin peptides for use in increasing vascularization in tissue with impaired blood flow
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
WO2009126698A2 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
US20120190042A1 (en) * 2009-01-22 2012-07-26 Reuben Gobezie Protein biomarkers and therapeutic targets for osteoarthritis
CN107970445B (en) 2009-03-30 2021-09-07 阿塞勒隆制药公司 BMP-ALK3 antagonists and uses for promoting bone growth
EP2427572B1 (en) * 2009-05-01 2013-08-28 Illumina, Inc. Sequencing methods
MX371080B (en) * 2009-06-23 2020-01-15 Univ California Enhancement of bmp retention.
US9409983B2 (en) * 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
EP2536432B1 (en) * 2010-02-19 2018-08-08 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
JP5616973B2 (en) * 2010-02-26 2014-10-29 オステムインプラント カンパニー リミテッド Oligopeptides that enhance osteoblast differentiation
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
EP2569253A4 (en) 2010-05-14 2013-10-02 Beth Israel Hospital Extracorporeal devices and methods of treating complications of pregnancy
WO2011160062A2 (en) * 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
WO2012006633A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
WO2012092566A1 (en) * 2010-12-30 2012-07-05 Surmodics, Inc. Cell attachment coatings and methods
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US8507446B2 (en) * 2011-08-09 2013-08-13 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating liver cirrhosis
EP2802606B1 (en) 2012-01-10 2018-04-25 Biogen MA Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US9920295B2 (en) * 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9133440B2 (en) * 2012-09-27 2015-09-15 Claresa Levetan Generation of new pancreatic beta cells
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
AR095527A1 (en) 2013-03-15 2015-10-21 Biogen Idec Inc FC-FACTOR IX POLYPEPTIDE FORMULATIONS IX
BR112016000546A2 (en) 2013-07-12 2017-11-21 Ophthotech Corp methods to treat or prevent eye conditions
BR112016011930A2 (en) * 2013-12-23 2017-09-26 Alk Abello As Peptide Combinations And Their Uses In Dust Mite Allergy Treatment
MD20170020A2 (en) * 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2015339130C1 (en) 2014-10-31 2021-03-18 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
WO2016127000A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
ES2901455T3 (en) 2015-04-03 2022-03-22 Univ Massachusetts Oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
JP2019503394A (en) 2016-01-31 2019-02-07 ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts Branched oligonucleotide
JP7021099B2 (en) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド Bound protein and how to use it
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts Conjugated oligonucleotides
EP3833763A4 (en) 2018-08-10 2023-07-19 University of Massachusetts Modified oligonucleotides targeting snps
AU2022299169A1 (en) 2021-06-23 2024-02-08 Beth Israel Deaconess Medical Center, Inc. Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61272063A (en) * 1985-05-29 1986-12-02 東レ株式会社 Mask
JPH0638860B2 (en) * 1986-06-30 1994-05-25 日本バイリ−ン株式会社 Molding mask
DE3735787A1 (en) * 1987-09-22 1989-03-30 Stiftung Inst Fuer Werkstoffte METHOD AND DEVICE FOR SPRAYING AT LEAST ONE JET OF A LIQUID, PREFERABLY MOLTED METAL
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
DE69030660T2 (en) * 1989-03-24 1997-09-25 Univ California ENDOTHELIAL CELL GROWTH FACTOR, INSULATION AND EXPRESSION
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
JPH06339542A (en) * 1994-04-20 1994-12-13 Asahi Chem Ind Co Ltd Dusting mask
JPH08107939A (en) * 1994-10-11 1996-04-30 Takehiko Tatsumi Mask
JP4251677B2 (en) * 1997-10-13 2009-04-08 大和紡績株式会社 Disposable mask
JP3578631B2 (en) * 1998-06-16 2004-10-20 サンエム・パッケージ株式会社 mask

Also Published As

Publication number Publication date
US5194596A (en) 1993-03-16
JP2007068545A (en) 2007-03-22
JP3523645B2 (en) 2004-04-26
DK0484401T3 (en) 1996-09-30
DE69028535D1 (en) 1996-10-17
ES2094159T3 (en) 1997-01-16
DE69028535T2 (en) 1997-04-10
EP0484401A1 (en) 1992-05-13
JP2004000255A (en) 2004-01-08
AU6079890A (en) 1991-03-11
EP0484401B1 (en) 1996-09-11
JPH10309191A (en) 1998-11-24
CA2063810C (en) 2003-02-04
JPH05501350A (en) 1993-03-18
WO1991002058A1 (en) 1991-02-21
ATE142693T1 (en) 1996-09-15
EP0484401A4 (en) 1992-08-19

Similar Documents

Publication Publication Date Title
CA2063810A1 (en) Production of vascular endothelial cell growth factor
CA2026915A1 (en) Stem cell factor
IL98255A0 (en) Biocompatible perforated membranes,processes for their use as a support in the in vitro growth of epithelial cells,the artificial skin obtained in this manner,and its use in skin grafts
CA2054699A1 (en) Growth of vascular endothelial cell growth factor and dna encoding same
AU1301792A (en) Anti-sense regulation of gene expression in plant cells
ES8606396A1 (en) Cell lines and their use for the production of proteins.
CA2290481A1 (en) Peptide-coated implants and processes for their preparation
AU7945682A (en) Rennin from recombinant dna
IT8547834A0 (en) PROCEDURE FOR TREATMENT OF CELLS WITH SOLUBLE BONE PROTEINS TO MAKE THEM SUITABLE FOR STIMULating THE GROWTH OF CARTILAGINE AND BONE TISSUES, AND THE PRODUCT OBTAINED
JPS6463505A (en) Cosmetics
EP0424416A4 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
IL96347A (en) Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells
AU2179688A (en) Recombinant eukaryotic cells production interleukin-2, process and vectors for their preparation and process for the preparation of interleukin-2
HU895788D0 (en) Process for producing peptides and medical products containing them
AU7899694A (en) BCRF1 proteins as inhibitors of interferon-y
IL96143A0 (en) Methods for the production of proteins and polypeptides and for enhancement of cell growth
AU7195191A (en) Process for production of exogenous gene or its product in plant cells
GR3033600T3 (en) Transformed endothelial cells.
NZ222089A (en) Endothelial cell harvester with irrigation means for enzyme treatment of blood vessel
ZA903485B (en) Production of vascular endothelial cell growth factor and dna encoding same
AU645998C (en) Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells
AU5966790A (en) Genetic elements useful in production of active protein
ZA902268B (en) Endothelial cell growth factor,methods of isolation and expression
GB8926286D0 (en) The production of enzymes from continuous plant cell suspension culture
AR243231A1 (en) Procedure for producing means for the in vitro culture of cells.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry